Nirsevimab Shows Strong Real-World Protection Against Severe RSV in Infants: Lancet Dr. Kamal Kant Kohli7 May 2025 9:15 PM ISTA meta-analysis indicates that the monoclonal antibody nirsevimab offers significant real-world protection against severe respiratory syncytial virus...
Timing of RSV Immunization Matters for Infant Protection suggests study Dr. Kamal Kant Kohli5 May 2025 8:30 PM ISTThe seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring its effectiveness,...
Prenatal Vaccination and Infant Monoclonal Antibody Combo Effective RSV Prevention Strategy: JAMA Medha Baranwal24 Feb 2025 8:45 PM ISTUSA: Researchers have found in a new study that a respiratory syncytial virus (RSV) prevention strategy combining prenatal vaccination and infant...
Sanofi Healthcare India gets CDSCO Panel nod to study Nirsevimab Dr. Divya Colin22 Jan 2025 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted approval to the drug...
AstraZeneca-Sanofi Beyfortus approved in Japan for prevention of RSV disease in infants Ruchika Sharma31 March 2024 12:30 PM ISTCambridge: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of...
Sanofi Gets CDSCO Panel Nod To Import, Market Nirsevimab to Treat Respiratory Syncytial Virus Disease Dr. Divya Colin27 March 2024 6:00 PM ISTNew Delhi: Pharmaceutical major Sanofi Healthcare India has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug...
Nirsevimab found Effective in Preventing RSV-Associated Hospitalizations Among Infants in new research Dr.Niharika Harsha B11 March 2024 12:45 AM ISTIn a significant development in pediatric healthcare, nirsevimab, a long-acting monoclonal antibody, has demonstrated robust real-world...
AstraZeneca-Sanofi Beyfortus gets nod for RSV disease prevention in infants in China Ruchika Sharma2 Jan 2024 3:06 PM ISTChina: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of...
Nirsevimab effective in preventing hospitalization for RSV associated lower RTI in infants Aditi29 Dec 2023 7:00 PM ISTRespiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection in young children and infants, leading to...
AAP Recommends Nirsevimab to Protect Infants Against Severe RSV: Monoclonal Antibody Gains Traction Dr. Kamal Kant Kohli18 Aug 2023 9:45 AM ISTUSA: The American Academy of Pediatrics (AAP) has released recommendations for the use of the monoclonal antibody nirsevimab for the prevention of...
AstraZeneca-Sanofi Nirsevimab unanimously recommended by USFDA Advisory Committee for prevention of RSV in infants Ruchika Sharma9 Jun 2023 1:30 PM ISTLondon: The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously 21 to 0 that AstraZeneca and...
Nirsevimab delivers 83 percent reduction in RSV infant hospitalizations in a real world clinical trial setting: Sanofi Ruchika Sharma14 May 2023 2:00 PM ISTRSV is the most common cause of LRTD, including bronchiolitis and pneumonia, in infants.
